Literature DB >> 15937433

Reversible optic neuropathy associated with low-dose methotrexate therapy.

Gerry Clare1, Stephen Colley, Robin Kennett, John S Elston.   

Abstract

A 66-year-old woman had progressive bilateral optic neuropathy with dense central scotomas and dyschromatopsia. She had been taking oral methotrexate 2.5 mg three times per week for rheumatoid arthritis for the previous 10 months (total intake 322.5 mg) without folic acid supplementation. She had never smoked or abused alcohol and her diet was healthy. Serum folate was reduced at 1.6 ng/mL (normal >4 ng/mL) and vitamin B12 levels were normal. After stopping methotrexate and after administration of oral folic acid, she experienced complete recovery of vision. Serum folate levels returned to normal during folic acid treatment but decreased to below normal once folic treatment was stopped. The persistently low folate level remains unexplained and may reflect a genetic defect in folate metabolism. Methotrexate can cause toxic side effects resulting from folate inhibition but has not been shown definitively to cause a reversible optic neuropathy associated with low serum folate.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15937433     DOI: 10.1097/01.wno.0000166061.73483.ce

Source DB:  PubMed          Journal:  J Neuroophthalmol        ISSN: 1070-8022            Impact factor:   3.042


  13 in total

1.  [Nervous system side effects of disease modifying treatments of rheumatoid arthritis].

Authors:  A Rubbert-Roth; H-F Petereit
Journal:  Z Rheumatol       Date:  2012-09       Impact factor: 1.372

2.  Adalimumab and Non-Arteritic Anterior Ischaemic Optic Neuropathy: A Case Report.

Authors:  Krista Kinard; Jessica A Walsh; Gopi K Penmetsa; Judith E A Warner
Journal:  Neuroophthalmology       Date:  2014-09-10

Review 3.  Neuro-ophthalmic sarcoidosis.

Authors:  Robert P Baughman; Kenneth L Weiss; Karl C Golnik
Journal:  Eye Brain       Date:  2012-03-13

Review 4.  Ocular side effects of anti-rheumatic medications: what a rheumatologist should know.

Authors:  V Peponis; V C Kyttaris; S E Chalkiadakis; S Bonovas; N M Sitaras
Journal:  Lupus       Date:  2010-02-09       Impact factor: 2.911

Review 5.  Ocular, Auricular, and Oral Manifestations of Inflammatory Bowel Disease.

Authors:  Sean Fine; Judy Nee; Pranjal Thakuria; Brian Duff; Francis A Farraye; Samir A Shah
Journal:  Dig Dis Sci       Date:  2017-10-24       Impact factor: 3.199

6.  Clinical approach to optic neuropathies.

Authors:  Raed Behbehani
Journal:  Clin Ophthalmol       Date:  2007-09

Review 7.  Ocular complications associated with systemic medications used in allergy/immunology practice.

Authors:  Avinash Gurbaxani; Clare L Fraser; Simon E Skalicky; Peter McCluskey
Journal:  Curr Allergy Asthma Rep       Date:  2013-06       Impact factor: 4.806

8.  Methotrexate for ocular inflammatory diseases.

Authors:  Sapna Gangaputra; Craig W Newcomb; Teresa L Liesegang; R Oktay Kaçmaz; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne; C Stephen Foster; John H Kempen
Journal:  Ophthalmology       Date:  2009-09-12       Impact factor: 12.079

9.  Resolution of recalcitrant uveitic optic disc edema following administration of methotrexate: two case reports.

Authors:  Se Joon Woo; Mi Jeung Kim; Kyu Hyung Park; Yun Jong Lee; Jeong-Min Hwang
Journal:  Korean J Ophthalmol       Date:  2012-01-14

10.  Obesity as a Potential Risk Factor for Vincristine-induced Peripheral Neuropathy.

Authors:  Tammy J Sajdyk; Frances A Boyle; Kaitlin S Foran; Yan Tong; Pankita Pandya; Ellen M L Smith; Richard H Ho; Elizabeth Wells; Jamie L Renbarger
Journal:  J Pediatr Hematol Oncol       Date:  2020-10       Impact factor: 1.170

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.